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Abstract
Inflammatory bowel disease (IBD) has become an increasingly frequent chronic health
problem in the last few decades, particularly in developing countries. In young adults, one
of the most common forms of IBD is Crohn’s disease (CD). CD is a multifactorial genetic
disease characterized by a transmural granulomatous inflammation that especially affects
the terminal ileum and the colon. As it involves defective inflammatory pathways, the
immune adaptive complex, and environmental factors, this disease has periods of remis-
sion and recurrence followed by diarrhea, abdominal pain, and malnutrition, which often
lead to lumen bowel stenosis associated to multiple fistulas. In addition, the growth of
mesenteric adipose tissue (MAT) near the affected intestinal area is a hallmark of CD.
Evidence linking the development of mesenteric and intestinal alterations in CD is increas-
ing. The aim of this chapter is to address adipose tissue in general, the morphological and
functional differences between its compartments, the main characteristics of MAT in CD,
and its possible role in the etiopathology of this immune-mediated disease.
Keywords: Crohn’s disease, inflammatory bowel disease, adipose tissue, mesenteric
adipose tissue, inflammation
1. Introduction
Adipose tissue was initially described as an energy storehouse. However, in the last decades, it
has also come to be recognized as an endocrine organ with multiple functions. Adipose tissue
is composed of adipocytes, connective and nerve tissue, fibroblasts, chondrocytes, osteocytes,
myocytes, and immune system cells, which constitute the stromal vascular fraction [1–3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Adipose tissue is very dynamic, and it is able to secrete a diverse spectrum of biologically
active substances designated as adipocytokines, such as cytokines, and hormone-like proteins,
such as leptin, adiponectin, and resistin. These substances exhibit endocrine or paracrine
functions, and they are important in maintaining energy homeostasis [1, 3–6].
Recent studies have shown that abnormal adipose tissue expansion associated with inflamma-
tion predisposes, in turn, to obesity, cardiovascular disease, chronic kidney disease, and
inflammatory bowel disease [5, 7–9].
This chapter deals with adipose tissue in general, the morphological and functional differences
among its compartments, and presents the main characteristics of mesenteric adipose tissue
(MAT) in Crohn’s disease (CD), in addition to its possible role in the etiopathology of the
disease.
2. Morphological classification of adipose tissue depots
Adipose tissue can be classified into white adipose tissue (WAT), brown adipose tissue (BAT),
and the recently discovered beige adipose tissue (BAT) [2, 10].
WAT comprises the vast majority of adipose tissue in the human body. WAT presents an
energy-storing property and a secretory function [3–5]. WAT is anatomically divided into
distinct depots: subcutaneous and visceral fat [2, 9].
Several studies have reported morphological and functional differences between these adipose
tissue compartments. Obese patients have visceral adiposity and are more prone to develop
insulin resistance, which strongly correlates with metabolic syndrome. Moreover, the pattern
of adipokines secreted by visceral and subcutaneous adipose tissue is different [2, 9, 11].
The importance of anatomical parameters in the regulation of WAT biology is highlighted by
the fact that in obese subjects abdominal deep subcutaneous WAT expands much more than
superficial subcutaneous WAT [1, 9, 12]. A further instance of this can be seen in that subcuta-
neous and visceral WAT contribute to cardiovascular disease, whereas femoral WATmay have
an overall protective effect. Therefore, changes in biological characteristics of different depots
of adipose tissue give rise to different cardiometabolic conditions [9, 13].
Indeed, the heterogeneity among different anatomical depots also appears to stem from their
intrinsic diversity, including cellular developmental origin, proliferative capacity, glucose and
lipid metabolism, insulin sensitivity, cytokine pattern, thermogenic ability, and vascularization
[1, 2, 5].
The features of obesity lie not only in WAT expansion but also in WAT dysfunction associated
with qualitative changes in its biological characteristics. In an obese condition, the ingestion of
excess nutrients and energy results in hypertrophy, consequent rupturing of adipocytes, and
increased local inflammatory cell accumulation, including macrophages, T cells, and altered
production of adipokines. These adipose tissue changes and their systemic consequences lead
to the concept of obesity as a chronic inflammatory state, and they increase the risk for
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multiple chronic diseases, such as type 2 diabetes, cardiovascular disease, several types of
cancer, and inflammatory bowel disease (IBD) [1, 3, 5, 9].
At a molecular level, BAT is distinguished fromWAT by its expression of uncoupling protein 1
(UCP1), which is crucial to mitochondrial heat production and is involved in the maintenance
of body temperature [10, 14, 15]. Neonates exhibit a considerable amount of BAT and a larger
fraction of total adipose tissue mass. The thermogenic function of BAT in human neonates has
not been yet well assessed due to the absence of safe experimental protocols. Probably, neo-
nates activate a non-shivering thermogenesis (NST) in order to prevent hypothermia [14, 16].
Adult humans exhibit another mechanism to produce heat, and BAT mass seems reduced
when compared with neonates. Currently, the activity of BAT in humans shows an inverse
correlation to age, body mass index, and the glucose level. Adult humans possess functional
BAT in the neck, supraclavicular, and axillary regions, as well as around major vessels, such as
the aorta [15, 16].
Thermogenesis is a major function of BAT in rodent and adult humans. Recent advances
showed that this tissue may also regulate glucose and lipid metabolism and that it plays a role
in regulating energy homeostasis in humans. However, little is still known about secreted
adipocytokines in vivo and their role in the regulation of energy metabolism. Studies have
shown that transplanted BAT from a healthy mouse into obese-induced and leptin-deficient
(ob/ob) mice improves whole-body energy metabolism, increasing insulin sensitivity and
reversing preexisting obesity. These effects were accompanied by modulation in the secretion
of interleukin (IL)-6, adiponectin, and others cytokines [14, 15].
Recently, another type of adipose tissue, described as beige, has been described. Exposure to
cold or to β3-adrenoceptor agonist treatment stimulates WAT. This tissue expresses large
amount of UCP1, which can perform a thermoregulatory function. Besides that, beige adipose
tissue exists within WAT, mainly in the supraclavicular region, and may be revealed by potent
exposure to cold under experimental conditions [10, 14, 15].
Classical brown adipocytes and beige cells play a critical role in the maintenance of body
temperature in a cold environment. Therefore, brown and beige adipocytes are promising
targets for the treatment of obesity and its related metabolic disorders [10, 14, 15].
Progress in understanding the morphological characteristics of adipocytes, as well as under-
standing how immune cells contribute to the control of the immunometabolism can provide
new potential targets of intervention. The formation of heat-producing beige adipocytes in
WAT and the polarization of macrophages transitioning from an inflammatory phenotype
toward an anti-inflammatory one are examples of potential targets to explore [5, 10, 14, 15].
Several studies have come out recently concerning the typically increased mesentery in CD
(named “creeping fat”) near the affected intestinal area. Histological characteristics of the MAT
in CD with reduced adipocyte size independent of the weight body have also been reported
[17, 18]. However, humoral and cellular changes in this adipose tissue are specific and differ
from those observed in hypertrophied fat tissue of obese patients. The functional impact of
MAT on CD development and progression is not clear yet and has been studied intensively in
recent years.
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3. Characteristics of mesenteric adipose tissue and its possible role in
Crohn’s disease etiopathology
IBD has become an increasingly widespread chronic health problem throughout the last few
decades, particularly in developing countries. In young adults, one of the most common forms of
IBD is CD. CD is a multifactorial genetic disease characterized by transmural granulomatous
inflammation, which affects mainly the terminal ileum and the colon. Defective inflammatory
pathways, immune adaptive complex, and environmental factors are involved in CD. This
disease presents periods of remission and recurrence followed by diarrhea, abdominal pain,
and malnutrition, which often lead to lumen bowel stenosis associated to multiple fistulas [19].
Evidence linking the development of mesenteric and intestinal alterations in CD is increasing. It
has been suggested that increased visceral adiposity (of which mesenteric fat is the main compo-
nent) is pathognomonic of CD. The involvement of MAT is increasingly thought to provide a
mechanistic contribution to CD progression. In addition, the increased MAT near the affected
intestinal area is considered a hallmark of an active and more aggressive CD [20–22].
For over a century, mesenteric anatomy has been universally depicted in an inaccurate manner.
Recent observations confirm a simpler and continuous structure from the duodenojejunal
flexure to the mesorectum [23, 24]. In a prospective observational study of a cohort submitted
to total excisional surgery of the mesocolon, it was demonstrated that the mesentery binds in
all intestinal segments [25, 26]. The mesentery is located between the intestines and the
abdominal wall, although the greatest mass of MAT is present in the ileocecal region [23].
This ectopic inflamed tissue in CD patients, also referred as “creeping fat,”was already identified
by Crohn and collaborators in 1932 [27]. He described its thickening and suggested its possible
involvement in CD, even though direct evidence was still lacking. MAT from CD patients
presents a large phenotypic variation according to what is observed in surgical specimens, with
notorious thickening of adipose tissue near the affected intestinal area when compared to
patients who do not present CD. Therefore, surgeons are familiar with the phenotypic variation
of the creeping fat, and it is used as an anatomical marker to delineate the extent of active disease
in CD patients (see Figure 1) [28, 29].
Considering the microscopic appearance of the MAT in CD, the histopathology shows
immune cell infiltration, and the adipocytes are smaller (lower mean area and perimeter) than
the controls, displaying an intriguing feature [17]. To investigate this morphological feature,
apoptosis was studied in these tissues. Analysis by TUNEL assay showed a significantly lower
number of apoptotic cells in the MAT of CD when compared to MAT of control group [18].
There was a strong positive correlation between the adipocyte size and the apoptotic index
(accessed by TUNEL). In addition, immunohistochemistry for Ki-67 was performed on all
MAT samples to access the proliferation rate of the adipocytes. However, no evidence of
proliferation was verified in MAT from both groups [18]. In fact, proliferation of adipocytes
occurs only in severe obesity, which produces an increased adipocyte count. Surprisingly, we
have an interesting situation in CD, in which the tissue looks like a MAT from a severely obese
patient, but the proliferation rate is zero. Whether adipocytes migrate to the affected area or
mesenchymal cells differentiate to adipocytes/fibroblasts has to be further investigated.
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Another microscopic feature is the adipocyte hyperplasia in the submucosa of CD creating a
similar histologic feature seen in the mesentery [30]. However, only colonic specimens were
evaluated. This characteristic was not verified in samples from ileal CD [31]. For this reason,
further investigation is needed, but fibrocytes may play a role in this, for they are increased in
the mesentery of CD [32].
Indeed, MATmay present a role in the etiopathology of CD. As it has been demonstrated with
other fat deposits, MAT is able to propagate both metabolic and inflammatory signals system-
ically, potentially modulating clinical features of CD. Its location allows MAT to respond to
environmental stimuli and to coordinate intestinal responses locally and systemically [33–35].
The importance of various mesenteric components in the development and maintenance of
CD, such as blood vessels, lymph nodes, and nerves, is reported [24, 26, 36, 37]. Although this
relationship has not been completely elucidated, some studies provide evidence for the MAT
component role in CD, as will be highlighted in the following paragraphs.
A recent study showed the presence of fibrosis, inflamed perivascular, thickened lymphatic
vessels, infiltration of stromal cell, perineuronal chronic inflammation, engorgement of vasa
recta, and small-sized adipocytes of MAT in patients with active CD [38]. MAT is divided into
avascular and vascular regions. Within the vascularized segments, the fibro-adipose tissue
involves large vessels and their ramifications [24, 39]. In healthy individuals, the mesentery is
soft, and it can be easily separated from the vascularized area. However, when affected by CD,
the mesentery thickens, and it interferes in the surgical dissection [28, 29].
Besides these features, histopathological findings, such as vascular lesions, focal arteritis, fibrin
deposition, arterial occlusion, and granulomatous vasculitis, are observed in CD patients. These
alterations demonstrate the role of mesenteric blood vessels in chronic intestinal inflammation
[38, 40, 41]. Changes in vascular endothelium and abnormal leukocyte recruitment were also
verified in CD [42]. Moreover, increase in the microvascular density and dysregulated angio-
genic activities are other morphological and functional findings in the gut of CD patients [43].
Figure 1. Surgical aspects of creeping fat (mesenteric adipose tissue) in the ileum affected by Crohn’s disease. The arrows
in (A) indicate the inflamed small bowel surrounded by the creeping fat. The blue line in (B) shows contiguous longitu-
dinal ulcer in the intestinal mucosa localized in the mesenteric face of the bowel (source: Archives of Colorectal Surgery
Unit—UNICAMP).
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Concerning immune cells, Kredel and collaborators identified an increase of regulatory M2
macrophages in the mesentery of CD, which suggests a protective role of the mesentery in this
disease [44].
Zuo and collaborators demonstrated that the function and morphology of the normal MAT in
CD patients were similar to control tissues [45]. However, increased MATadjacent to involved
ileum in CD was dysfunctional, exhibiting higher expression of hypoxia-inducible factor 1α
when compared to controls, which suggests hypoxia in this tissue.
Moreover, the mesenteric nerves may also influence the pathogenesis, behavior, and prognosis
of CD. In an experimental study, functional and structural alterations were observed in the
mesenteric nerves of animals with colitis. Mice with colitis induced by trinitrobenzene sulfonic
acid or acetic acid presented hyperexcitability of visceromotor neurons causing changes in the
lower mesenteric ganglia during the intestinal inflammatory process [38, 46].
4. Molecular characteristics of the mesenteric adipose tissue in Crohn’s
disease
Recently, studies have highlighted a new function for MAT as an immune organ [47]. MAT’s
basic cellular components comprise adipocytes, preadipocytes, fibroblasts, mesenchymal stem
cells, and endothelial cells. However, when the inflammatory process is initiated, an increase
of immune effector cells occurs, including T cells, natural killer cells, and macrophages, as well
as innate immune cells [48]. These cells are responsible for the production of several pro- and
anti-inflammatory cytokines, such as TNF-α, IL-6, IL-8, IL-23, and IL-10 [49]. Given the poten-
tial therapeutic effect of their blockade, a large number of these inflammatory mediators
present in MAT and their role in the development of CD have been closely investigated [31].
One of the main pro-inflammatory cytokines in CD is TNF-α. TNF-α has a fundamental role in
CD due to the discovery of the therapeutic effect of its blockage [50]. The complete mechanism
by which TNF-α regulates MAT inflammation in CD patients has not yet been elucidated, but
it is likely a complex and multifactorial process. However, it is known that TNF-α inhibits the
proliferation of new adipocytes, which leads to an increased amount of free fatty acids [51].
Another important molecule in the inflammatory process is the peroxisome proliferator-activated
receptor (PPAR) transcription factor, which plays an essential role in the regulation of cellular
differentiation, development, and metabolism. In CD, it has some specific functions related to the
maintenance of the process, such as cytokine production, adipocyte differentiation, fibrocytes
differentiation inhibition, and IκB/NF-κB activation [33, 52, 53]. On the one hand, studies have
shown a decrease of the PPAR-γ in MAT from CD patients [53, 54]. On the other hand,
Desreumaux and collaborators showed that significant accumulation of intra-abdominal fat is
associatedwith overexpression of PPARY and TNF-α in theMATof the small bowel mesentery in
CD patients, which suggests adipocytes as one of the sources of TNF-α production [55].
Although adipose tissue is able to increase TNF-α secretion via leptin, a hormone produced by
adipocytes [56], some studies in the literature did not find high levels of TNF-α in the MATof CD,
neither higher levels of IL-1B, IL6, IL8, IL23, and NF-KB activation [21, 31, 38, 57]. Again, on the
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one hand, a decrease NF-kB pathway activation (decreased pIKB/IKB ratio) and increased IL-10
expression in MAT of CD patients have been demonstrated, which suggest a possible anti-
inflammatory role of MAT [21, 31]. On the other hand, STAT-1 transcription factor is activated in
the MAT of CD patients, suggesting a potential role in the inflammatory process [31]. This topic
needs further investigation due these conflicting findings. Figure 2 summarizes this differential
expression of molecular pathways in the MATand the intestinal mucosa of CD.
In another study, adiponectin, an anti-inflammatory adipokine, was produced and released by
adipose tissue that inhibited NF-κB activation in endothelial cells in MAT of CD patients [58].
However, Rodrigues and collaborators obtained low levels of serum and mesenteric adiponectin
in MAT of CD, which suggests a defect in this anti-inflammatory pathway, which could in turn
help to perpetuate a state of chronic inflammation [17]. Interestingly, all patients had the same
BMI, below 25, and this alteration was independent of this parameter and of the presence of
metabolic disorders. Resistin, another adipokine, was also studied and was verified to be
increased in MAT of CD. Resistin may have a pro-inflammatory role in the MAT and is corre-
lated with increased systemic C-reactive protein in CD patients [59].
Figure 2. Molecular pathways in the mesenteric adipose tissue and intestinal mucosa of Crohn’s disease patients (source:
By Support Didactic from the School of Medical Sciences—UNICAMP).
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Moreover, the autophagy pathways have been addressed in the last few years; for this process,
it is crucial for mucosal immunity, and there is a growing number of autophagy-related genes
associated with the development of CD [60–62]. Leal and collaborators demonstrated a reduc-
tion in autophagy markers in MAT of CD patients, which may maintain the inflammatory
response in the affected intestine [63]. In this study, LC3-II protein, which is indispensable for
the formation of autophagosome, was lower in the MAT of CD, suggesting an impairment of
the autophagy process in this tissue. The altered autophagy could lead to unprocessed unnec-
essary protein accumulation, which activates pro-inflammatory pathways implicated in the
pathogenesis of CD.
5. Conclusions
MATmay have an important role in CD inflammation, for it was possible to observe an altered
balance between pro-inflammatory and anti-inflammatory factors in this tissue, decreased
apoptosis, as well as defective autophagy. Available data indicate that mesenteric changes are
primarily anti-inflammatory but can ultimately cause inflammation in CD. Currently, the
mesenteric events in the chronology of CD are under discussion. MAT may be involved in the
maintenance of inflammation in the late stages of the disease and in the mechanism that leads
to relapses during the course of the disease. Moreover, the interaction between cytokines,
adipokines, transcription factors, adipose stem cells, vascular endothelia, and adipocyte plas-
ticity may imply in MAT remodeling, which certainly influences CD physiopathology.
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